This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Brown, R. C. Articles by Gwaltney, J. M. Search for Related Content PubMed PubMed Citation Articles by Brown, R. C. Articles by Gwaltney, J. M., Jr.

Mycoplasma pneumoniae Vaccine: Antigenicity of Buffered Antigens in Volunteers

¹ Departments of Internal Medicine and Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia 22901

ABSTRACT

The antigenicity of experimental Mycoplasma pneumoniae vaccines prepared from antigen grown in a medium buffered with N-2-hydroxyethylpiperazine-N'-2'-ethanesulfonic acid was tested in young, adult males. Formalin-inactivated antigens from a high-passage strain and a low-passage strain at various dilutions (12 to 123 µg of N/ml) were injected intramuscularly in 1-ml doses. Antibody responses were tested by the metabolic inhibition (MI) technique. Sixty-five to 86% of the volunteers in all vaccine groups responded with fourfold or greater MI antibody rises, but only nine (39%) of 23 antibody-free subjects converted compared to 53 (88%) of 60 of those with pre-existing antibody. A booster vaccination did not increase the number of converters or enhance the geometric mean titers. The antigen concentrations of vaccines with 24 or more µg of N/ml appeared to be above the threshold needed for maximal antibody responses in the dose range tested. MI antibody rises could not be detected in sputa and nasal washings obtained from a small group of vaccinees. The results of this study suggest that the new vaccines offer little or no improvement in antigenicity in man over earlier inactivated vaccines.